scorecardresearch
Monday, Jan 30, 2023
Advertisement
Premium

SC restrains Glenmark from selling copy of Merck’s diabetes drug

SC restrained Glenmark Pharmaceuticals from the manufacture and sales of anti-diabetes drug, Sitagliptin.

glenmark, supreme court, anti diabetes drug, sitagliptin, medicine, business news Glenmark Pharmaceuticals

 

By: Indu Bhan

The Supreme Court on Friday restrained Glenmark Pharmaceuticals from the manufacture and institutional sales of branded generic versions of anti-diabetes drug, Sitagliptin, till July 22 even as it allowed it to continue selling existing stocks, asking the trial judge to decide expeditiously on the company’s dispute with US-based Merck, which holds a patent on the drug.

[related-post]

Subscriber Only Stories
UPSC Key- January 30, 2023: Know about Project 39A, Beating Retreat Cerem...
UPSC Essentials | Key terms of the past week with MCQs
ExplainSpeaking: How to evaluate a Union Budget
Mahesh Vyas writes: Why the job shortage is for real

Meanwhile, drug major Sun Pharmaceutical said it is reviewing a complaint by Meijer Inc alleging anti-trust in connection with Ranbaxy securing market exclusivity for certain products. “Meijer filed complaint, alleging antitrust and RICO Act violations in connection with Ranbaxy securing market exclusivity as part of the FDA’s approval for certain products,” Sun Pharmaceutical said.

With inputs from PTI

First published on: 16-05-2015 at 02:15 IST
Next Story

MHA to clear air, underline L-G is administrative head

Latest Comment
Post Comment
Read Comments
Advertisement
Advertisement
Advertisement
Advertisement
close